AR-711 / Aridis - LARVOL DELTA

Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants (PRNewswire) - "Aridis Pharmaceuticals, Inc....announced today that it has augmented its inhaled AR-711 monoclonal antibody (mAb) to COVID-19 with a second mAb (AR-713)...Enhanced dual antibody cocktail will be delivered as an inhaled treatment...Aridis is pleased to announce preclinical development services support from NIAID....The Company remains on track to finalize the Phase 1/2/3 design for this program and obtain concurrence from the FDA and EMA in 1H 2021 such that patient enrollment can be initiated in 2H 2021."

New P1/2 trial • New P3 trial • Infectious Disease • Novel Coronavirus Disease

Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform on December 4th, 2020 (PRNewswire) - "Aridis Pharmaceuticals, Inc....is pleased to announce a 75 minute 'Fireside Chat Forum,' with its five covering analysts will be held on December 4th, 2020 at 11:00AM EST....AR-301: Currently enrolling a Phase 3 global clinical trial in patients with ventilator associated pneumonia (VAP)...for COVID-19. Interim data expected in 1H 2021; full data in YE 2021; COVID-19 (AR-711 & 701): Developing inhaled, self-administered, at-home treatment for mild-to-moderate condition (AR-711). A clinical Phase 1/2 study to be launched in 1H 2021. Continuing characterization of monoclonal antibody cocktail (AR-701) for intravenous inpatient treatment for moderate-severe indications."

Enrollment status • New P1/2 trial • P3 data • P3 data: top line • Infectious Disease • Novel Coronavirus Disease